COPD Biologics: Right Patient, Right Pathway, Right Time.

Area of Science:

• Pulmonary Medicine
• Immunology
• Precision Medicine

Background:

• Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a heterogeneous condition, moving beyond the traditional view of uniform neutrophilic inflammation.
• Recent advances in disease endotyping have identified distinct subgroups within COPD, suggesting potential for targeted immunomodulatory therapies.

Purpose of the Study:

• To review mechanistic insights and clinical trial data for biologic therapies targeting type 2 (T2) inflammation and epithelial alarmins in COPD.
• To explain the shift from ineffective neutrophilic inflammation targets to successful biomarker-driven approaches in COPD treatment.

Main Methods:

• Narrative review synthesizing data from mechanistic studies and clinical trials.
• Focus on biologic therapies targeting T2 cytokines (IL-5, IL-4/IL-13) and epithelial alarmins (IL-33, TSLP).
• Analysis of factors influencing therapeutic efficacy, including patient selection, disease stage, and intervention timing.

Main Results:

• Biomarker-driven selection has enabled success in specific COPD populations previously unresponsive to treatment.
• Targeting T2 inflammation and alarmin pathways represents a promising therapeutic avenue in COPD.
• Efficacy of biologics is contingent on precise patient stratification and appropriate timing of intervention.

Conclusions:

• The future of biologics in COPD involves integrating biomarkers, treatable traits, and longitudinal phenotyping.
• Aligning the right patient with the right biologic therapy at the right time is crucial for addressing treatment gaps.
• Precision medicine approaches hold the key to optimizing biologic therapy for COPD patients.